Briefing Archive

April 30, 2026 FDA Halts Newron’s Evenamide Schizophrenia Trial After Patient Death 44 articles April 29, 2026 FDA Fast-Tracks Psilocybin and Methylone for Mental Health, Signaling Shift in Psychedelic Psychopharmacology 34 articles April 28, 2026 Psilocybin Beats Nicotine Patches for Smoking Cessation in Novel Trial 30 articles April 27, 2026 FDA Approves Caplyta for Schizophrenia Relapse Prevention, Citing 63% Risk Reduction 25 articles April 26, 2026 HS-10380 Phase 3 Data: Novel Antipsychotic Challenges Aripiprazole in Acute Schizophrenia 38 articles April 25, 2026 Valproic Acid Cuts Clozapine Levels by Half; UGT Polymorphisms Demand Personalized Dosing 55 articles April 24, 2026 AXS-05 Shows Promise for Alzheimer Agitation Ahead of PDUFA; Novel Psychostimulant Safe in Psychosis History 65 articles April 23, 2026 FDA Ends Clozapine REMS; New Guidelines Address Prolactin Monitoring and Bipolar Relapse Risks 69 articles April 22, 2026 Trump's Psychedelic Order Accelerates Psilocybin Pathways While Xanomeline/Trospium Enters Schizophrenia Care 69 articles April 21, 2026 FDA-authorized Psilocybin PEX010 study shows promise; Ketamine fails in anesthesia trials 121 articles April 20, 2026 France Approves IV Ketamine for Suicidal Crisis; Novel α7nAChR Astrocyte Mechanism Explains Cognitive Trial Failures 103 articles April 19, 2026 Lithium Weight Gain: New Strategies to Improve Long-Term Adherence 78 articles April 18, 2026 Lilly's Tirzepatide Risks Greater Muscle Loss vs Semaglutide; Cochrane Challenges Alzheimer's Drugs 123 articles April 17, 2026 Lilly's obesity drug advances despite FDA liver concerns as RNA CAR-Ts enter autoimmunity trials 169 articles April 16, 2026 FDA demands safety data on Lilly's Foundayo amid breakthroughs in Alzheimer's detection and AI cardiac screening 174 articles April 15, 2026 FDA advances gene therapy safety and approves first FSGS drug; Revolution's pancreatic cancer therapy nearly doubles survival 174 articles April 14, 2026 Pancreatic cancer drug doubles survival time; FDA rejects Replimune's melanoma therapy 142 articles April 13, 2026 Pancreatic Cancer Drug Doubles Survival; Parkinson's Meds Metabolized by Gut Bacteria 63 articles April 12, 2026 FDA rejects Replimune cancer therapy; new biomarkers advance Alzheimer's, Parkinson's, and schizophrenia detection 64 articles April 11, 2026 Obesity drug risks rise as AI links loneliness to diabetes and trauma alters children's sensory processing 131 articles April 10, 2026 Genetics and Gut Microbes Drive New Breakthroughs in Obesity, Alzheimer's, and ALS Treatment 156 articles April 09, 2026 Novo launches high-dose Wegovy as FDA seeks new ad powers; mental health and neurology breakthroughs advance 150 articles April 08, 2026 Tepezza delivery shift, HIV pill under $5, and brain switches for eating and Alzheimer's dominate psychiatric breakthroughs 143 articles April 07, 2026 Neurocrine's $2.9B Soleno Acquisition and New Insights into Psychiatric MAID Eligibility 107 articles April 06, 2026 Trump's drug tariffs threaten psychiatric care; new insights reveal brain circuits for pain, memory, and reality perception. 137 articles April 05, 2026 Trump's drug tariffs threaten care; new research reveals brain circuits for pain, memory, and psychosis. 99 articles April 04, 2026 Lilly's oral GLP-1 approved alongside critical insights on EBV-MS links, SPT-neuropathy risks, and schizophrenia treatment evolution 121 articles April 02, 2026 FDA warns of Tavneos liver deaths; SCOT upholds conversion therapy; New Alzheimer's and antipsychotic breakthroughs emerge 183 articles